UnitedHealth Group (NYSE: UNH) reported better-than-expected earnings for the fourth quarter of 2019 while revenues matched estimates. Shares were down 0.40% in
UnitedHealth Group beats Q4 earnings estimates; revenues match expectations
Categories
pharmaceuticals
UnitedHealth (UNH) Q4 earnings preview: Get ready for another good show
UnitedHealth Group (NYSE: UNH) has been expanding its market value steadily, especially after reporting stronger-than-expected third-quarter results a few months ago. Since
Walgreens (WBA) Q1 profit drops 25%, misses estimates
Walgreens Boots Alliance Inc. (NASDAQ: WBA) reported a 25% drop in earnings for the first quarter of 2020 due to higher charges
New hope for investors as Amarin (AMRN) sees a promising year ahead
Though Amarin Corporation (NASDAQ: AMRN) has been showing signs of recovery since last year, after staying low for several years, the stock
Walgreens Boots Alliance (WBA) to report Q1 earnings: What’s in the offing?
Walgreens Boots Alliance (NYSE: WBA) entered the new fiscal after a disappointing show last year, in terms of shareholder return and financial
Will Rite Aid (RAD) stock soar in 2020 from its yearly high?
Rite Aid Corporation (NYSE: RAD) stock soared to a yearly high of $20.38 on Friday as investors were positive about the company's
Arrowhead Pharmaceuticals (ARWR): FY 2019 Earnings Snapshot
-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported earnings of 69 cents per share during fiscal year 2019, compared to a loss of
Aurinia Pharmaceuticals (NASDAQ: AUPH): Q3 2019 Earnings Snapshot
-- Aurinia Pharmaceuticals (NASDAQ: AUPH) reported a third-quarter 2019 loss of $0.21 per share versus a loss of $0.15 per share expected.
Titan Pharmaceuticals (TTNP): Q3 2019 Earnings Snapshot
-- Titan Pharmaceuticals (NASDAQ: TTNP) reported Q3 2019 loss of $0.18 per share, vs. $0.21 expected. -- Revenues fell 47% to approx.
Catalyst Pharmaceutical (CPRX): Q3 2019 Earnings Snapshot
-- Catalyst Pharmaceutical (NASDAQ: CPRX) reported third quarter 2019 earnings of $0.13 per share, vs. $0.11 per share expected. -- Net product
BioLineRx (BLRX): Q3 2019 Earnings Snapshot
-- BiolineRX (NASDAQ: BLRX) reported third quarter 2019 operating loss of $6.6 million vs. $6.2 million loss in the year-over period. --
Humana Inc (HUM): Q3 2019 Earnings Snapshot
-- Humana Inc. (NYSE: HUM) reported third-quarter 2019 earnings of $5.03 per share, vs. $4.58 per share expected. -- Total revenue rose
Perrigo Company (PRGO): Q3 2019 Earnings Snapshot
-- Perrigo Company plc (NYSE: PRGO) reported Q3 2019 earnings of $1.04 per share, vs. $0.93 expected. -- Sales grew 5.1% to
Mylan (MYL) Q3 earnings surpass estimates; revenues miss
Drugmaker Mylan (NASDAQ: MYL) reported third-quarter revenues that fell short of expectations. Meanwhile, earnings increased and surpassed the consensus estimate. The company
Endo International (ENDP): Q3 2019 Earnings Snapshot
-- Endo International plc (NASDAQ: ENDP) reported Q3 2019 earnings of $0.60 per share, vs. $0.53 expected. -- Revenues fell 2% to
Mallinckrodt plc (MNK): Q3 2019 Earnings Snapshot
-- Mallinckrodt plc (NYSE: MNK) reported third-quarter 2019 earnings of $2.07 per share, vs. $1.97 per share expected. -- Revenue fell 7%
Amarin’s Q3 results top estimates
Amarin Corporation plc (NASDAQ: AMRN) reported better-than-expected revenue and earnings for the third quarter of 2019, allowing the stock to gain 2%
AbbVie (NYSE: ABBV) Q3 profit dips 31% but beats estimates
AbbVie Inc. (NYSE: ABBV) reported a 31% dip in earnings for the third quarter of 2019 due to higher costs and expenses.
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG): Q3 2019 Earnings Snapshot
-- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) reported a net loss of $23.62 million or $0.70 per share for the third quarter of
Rite Aid swings to profit in Q2, stock gains strength
Pharmacy retailer Rite Aid Corporation (NYSE: RAD) swung to a profit in the second quarter of 2020, from a loss in the year-over
Ovid Therapeutics stock gains on positive epilepsy trial data
Ovid Therapeutics Inc. (NASDAQ: OVID) stock climbed to an 8-month high of $3.05 on Tuesday after positive initial data from rare epilepsies